Targher, Giovanni

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 4,472

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity

Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 2,456

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,907

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,747

The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments

Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 850

Current status and future trends of the global burden of MASLD

Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 781

Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis

Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G. (2021) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 674

The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

Karlsen, T. H., Sheron, N., Zelber-Sagi, S., Carrieri, P., Dusheiko, G., Bugianesi, E., Pryke, R., Hutchinson, S. J., Sangro, B., Martin, N. K., et al. (2022) · The Lancet

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 652

Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach

Targher, G., Tilg, H., & Byrne, C. D. (2021) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 586

Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals

Mantovani, A., Petracca, G., Beatrice, G., Tilg, H., Byrne, C. D., & Targher, G. (2021) · Gut

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 481

NAFLD as a driver of chronic kidney disease

Byrne, C. D., & Targher, G. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentChronic Kidney Disease and Diabetes

Cited by 449

Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., Schattenberg, J. M., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut

Liver Disease Diagnosis and TreatmentChronic Kidney Disease and Diabetes

Cited by 402

Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus

Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 397

Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Tilg, H., Byrne, C. D., & Targher, G. (2022) · Gut

Liver Disease Diagnosis and TreatmentCancer Risks and Factors

Cited by 363

Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 randomized trial)

Bacchi, E., Negri, C., Targher, G., Faccioli, N., Lanza, M., Zoppini, G., Zanolin, E., Schena, F., Bonora, E., & Moghetti, P. (2013) · Hepatology

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 350

Metabolic Dysfunction–Associated Steatotic Liver Disease

Targher, G., Valenti, L., & Byrne, C. D. (2025) · New England Journal of Medicine

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 325

Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease

Anstee, Q. M., Mantovani, A., Tilg, H., & Targher, G. (2018) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentCardiovascular Function and Risk Factors

Cited by 310

Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials

Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 299

Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function

Zoppini, G., Targher, G., Chonchol, M., Ortalda, V., Abaterusso, C., Pichiri, I., Negri, C., & Bonora, E. (2012) · Diabetes Care

Gout, Hyperuricemia, Uric AcidChronic Kidney Disease and Diabetes

Cited by 274

Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease

Scorletti, E., Afolabi, P. R., Miles, E. A., Smith, D. E., Almehmadi, A., Alshathry, A., Childs, C. E., Del Fabbro, S., Bilson, J., Moyses, H. E., et al. (2020) · Gastroenterology

Liver Disease Diagnosis and TreatmentGut microbiota and health

Cited by 237

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review

Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 230

Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes

Zoppini, G., Targher, G., Zamboni, C., Venturi, C., Cacciatori, V., Moghetti, P., & Muggeo, M. (2006) · Nutrition, Metabolism and Cardiovascular Diseases

Cardiovascular and exercise physiologyPhysical Activity and Health

Cited by 173

Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?

Valenti, L., Bugianesi, E., Pajvani, U., & Targher, G. (2016) · Liver International

Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 171

In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry

Targher, G., Dauriz, M., Laroche, C., Temporelli, P. L., Hassanein, M., Seferovic, P. M., Drozdz, J., Ferrari, R., Anker, S., Coats, A., et al. (2017) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 169